HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (NASDAQ: ARDM) (the "Company") today
announced that it will host a Key Opinion Leader (KOL) call on the topic
of infection management in non-cystic fibrosis bronchiectasis (NCFBE)
patients on Monday, September 18 at 11am Eastern Time.
The call will feature presentations by key opinion leaders Gregory Tino,
MD (University of Pennsylvania), Prof. James Chalmers (University of
Dundee), and Katie Laessig, MD (former FDA Deputy Director, Division of
Anti-Infective Products), who will discuss the current standard of care
for patients with NCFBE and the regulatory pathway for new treatments of
bronchiectasis. The KOLs will be available to answer questions at the
conclusion of the call.
Aradigm's management team will also provide a summary of the Company's
Phase 3 efficacy and safety data on Linhaliq™, an investigational
proprietary formulation of ciprofloxacin for inhalation. Linhaliq was
evaluated in two Phase 3 studies to determine its safety and
effectiveness as a once-a-day inhaled formulation for the chronic
treatment of patients with NCFBE who have chronic lung infections with Pseudomonas
aeruginosa (P. aeruginosa).
Gregory Tino, MD is an Associate Professor of Medicine at the Perelman
School of Medicine at the University of Pennsylvania in Philadelphia. He
is the Chief of the Department of Medicine at Penn Presbyterian Medical
Center and Senior Vice Chair of the Department of Medicine of the
Perelman School of Medicine at the University of Pennsylvania. Dr. Tino
is an inaugural member of the Academy of Master Clinicians at Penn
Medicine. Dr. Tino has a specific clinical and research interest in
bronchiectasis and interstitial lung diseases. He has been a Principal
or Sub-Investigator for several clinical trials in Idiopathic Pulmonary
Fibrosis and Bronchiectasis. He is Past-Chair of the Assembly on
Clinical Problems and has previously served on the Board of Directors of
the American Thoracic Society, of which he is currently a member.
Professor James D Chalmers is the British Lung Foundation Professor of
Respiratory Research, University of Dundee, Scotland. Prof. Chalmers did
his undergraduate training in Glasgow and trained in Respiratory
Medicine in Edinburgh before moving to Dundee, Scotland. He is a
Consultant Respiratory Physician and runs the regional bronchiectasis
service that cares for more than 600 patients with the disease, as well
as having an active clinical interest in COPD, severe asthma and cystic
fibrosis. He has published more than 150 peer reviewed publications and
books. He chairs with European Bronchiectasis Registry and recently
chaired the European Respiratory Society guidelines for bronchiectasis.
He is chair of the British Thoracic Society Respiratory Infection
Speciality Advisory Group, and is secretary of the European Board of
Accreditation in Pneumology (EBAP) which accredits continuing medical
education for respiratory physicians in Europe. In recognition of
Professor Chalmers as an outstanding international leader of lung
research, in 2017 he received the prestigious award by the British Lung
Foundation to advance research on bronchiectasis. He also received the
Romain Pauwels award, the highest scientific award from the European
Respiratory Society, and the Patrick Neill Medal from the Royal Society
of Edinburgh in 2017 for his contributions to bronchiectasis.
Dr. Katie Laessig is currently Senior Vice President of Regulatory
Affairs and Medical Safety at RRD International, LLC. Dr. Laessig is a
16-year Food and Drug Administration (FDA) veteran and served as Deputy
Director of the Division of Anti-Infective Products (DAIP), where she
was responsible for review of antimicrobial drug and biologic products
for the treatment as well as prevention of infectious diseases. Prior to
joining DAIP, she held several positions of increasing responsibility
within the Division of Anti-Viral Products (DAVP). She is board
certified in infectious diseases and is a member of the Infectious
Disease Society of America and the American Society for Tropical
Medicine and Hygiene. Dr. Laessig earned her medical degree from the
University of Maryland in Baltimore in 1992 and completed her internal
medicine residency in 1995 and infectious diseases fellowship in 1997,
both at George Washington University Medical Center in Washington, D.C.
Monday, September 18, 2017 @ 11am
Eastern Time/8am Pacific Time
If you would like to ask a question during the live Q&A, please submit
your request via email at Questions@LifeSciAdvisors.com.
About Non-Cystic Fibrosis Bronchiectasis
Non-cystic fibrosis bronchiectasis (NCFBE) is a severe, chronic and rare
disease characterized by abnormal dilatation of the bronchi and
bronchioles, frequently associated with chronic lung infections. It is
often a consequence of a vicious cycle of inflammation, recurrent lung
infections, and bronchial wall damage. NCFBE represents an unmet medical
need with high morbidity and mortality that affects more than 150,000
people in the U.S. and over 200,000 people in Europe. There is currently
no drug approved for the treatment of this condition. NCFBE patients who
have chronic infections with P. aeruginosa have a 6.5-fold
increase in hospitalization, three times higher mortality, and a worse
quality of life compared with those without P. aeruginosa
Aradigm is an emerging specialty pharmaceutical company focused on the
development and commercialization of drugs for the prevention and
treatment of severe respiratory diseases. Aradigm has completed two
Phase 3 clinical trials with Linhaliq, an investigational proprietary
formulation of ciprofloxacin for inhalation, for the treatment of NCFBE
and submitted a New Drug Application to the FDA for this indication.
Aradigm's inhaled ciprofloxacin formulations, including Linhaliq, are
also product candidates for treatment of patients with cystic fibrosis
and non-tuberculous mycobacteria, and for the prevention and treatment
of high threat and bioterrorism infections, such as inhaled tularemia,
pneumonic plague, melioidosis, Q fever and inhaled anthrax.
More information about Aradigm can be found at www.aradigm.com.
Aradigm and the Aradigm Logo are registered trademarks of Aradigm
Corporation. Linhaliq is a registered trademark of Grifols, S.A.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170915005165/en/
Nancy Pecota, 510-265-8800
Source: Aradigm Corporation
News Provided by Acquire Media